Sign In
Buy NBIX
$165.11
+10.27 (+6.63%)
At Close: Jun 03, 2026
Neurocrine Adds to Pipeline With $2 Billion Takeda Deal
08:04pm, Wednesday, 17'th Jun 2020
Biotech gets 7 drugs in partnership, 3 of which are in phase 2 testing Continue reading...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bausch Health
Viva plots natural gas imports to key Victorian city - DirectorsTalk
09:42am, Wednesday, 17'th Jun 2020
Viva Energy believes Geelong in Victoria is well posited for the company to establish a liquefied natural gas (LNG) import, supply and storage facility. The company expects the project would bring nat
Neurocrine Biosciences (NASDAQ:NBIX) Receives New Coverage from Analysts at Needham & Company LLC
09:40am, Wednesday, 17'th Jun 2020
Needham & Company LLC initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a report published on Tuesday, TipRanks reports. The brokerage issued a hold rating on the stock. Other an
Oppenheimer Assigns a Buy Rating on Neurocrine (NBIX) - Markets
08:39pm, Tuesday, 16'th Jun 2020
In a report released today, Jay Olson from Oppenheimer assigned a Buy rating to Neurocrine (NBIX – Research Report), with
Neurocrine (NBIX) Gets a Hold Rating from Needham - Markets
05:29pm, Tuesday, 16'th Jun 2020
Needham analyst Alan Carr assigned a Hold rating to Neurocrine (NBIX – Research Report) today. The company’s shares closed last
Comunicado do Business Wire :Takeda Pharmaceutical Company Limited & Neurocrine Biosciences, Inc.
04:01pm, Tuesday, 16'th Jun 2020
A Neurocrine Biosciences, Inc
Ultragenyx Pharmaceutical: Near-Term Catalysts Offer Best Of Both Worlds (NASDAQ:RARE)
03:00pm, Tuesday, 16'th Jun 2020
Ultragenyx is awaiting two new FDA approvals in the coming weeks. Two more candidates are undergoing mid-stage studies with data readouts expected before the ye
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
11:01am, Tuesday, 16'th Jun 2020
Strategic partnership agreement provides Neurocrine Biosciences exclusive worldwide rights to early-to-mid-stage psychiatry pipeline compounds within Takeda’s Neuroscience portfolio Collaboration i�
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
11:00am, Tuesday, 16'th Jun 2020
Neurocrine Biosciences and Takeda announced a strategic collaboration for compounds in Takeda’s early-to-mid-stage psychiatry pipeline.
The Chief Research Officer of Neurocrine is Exercising Options - Markets
01:35am, Tuesday, 16'th Jun 2020
Yesterday it was reported that the Chief Research Officer of Neurocrine (NBIX – Research Report), Dimitri Grigoriadis, exercised options to
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
12:00am, Tuesday, 16'th Jun 2020
Neurocrine Biosciences and Takeda announced a strategic collaboration for compounds in Takeda’s early-to-mid-stage psychiatry pipeline.
Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference
08:01pm, Monday, 15'th Jun 2020
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2020 Napa Biopharma Conference at 2:00 p.m. PT (5:00 p.m. ET) on Monday, June 22, 2020. Kevin Gorman, Chief E
